drugset / Trial / NCT03322800
A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will characterize the pharmacokinetics (PK) of AK0529, the effect of food and evaluate the safety of AK0529 in healthy Chinese adult subjects. 50 subjects will be randomized to receive a dose level of AK0529 or placebo in five groups. The total study duration will be approximately 18-27 days for each subject.
Timeline
- Start
- 2017-10-23
- Primary completion
- 2018-04-06
- Completion
- 2018-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ziresovir | Small molecule | 100 mg | Oral |
| Subject | Ziresovir | Small molecule | 300 mg | Oral |
| Subject | Ziresovir | Small molecule | 600 mg | Oral |
Indications
No indication recorded.